| Item Type | Name |
|
Concept
|
Protein-Tyrosine Kinases
|
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
|
Concept
|
Focal Adhesion Protein-Tyrosine Kinases
|
|
Concept
|
fms-Like Tyrosine Kinase 3
|
|
Academic Article
|
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
|
|
Academic Article
|
BCR/ABL induces multiple abnormalities of cytoskeletal function.
|
|
Academic Article
|
The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells.
|
|
Academic Article
|
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
|
|
Academic Article
|
Role of focal adhesion proteins in signal transduction and oncogenesis.
|
|
Academic Article
|
The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase.
|
|
Academic Article
|
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
|
|
Academic Article
|
The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin.
|
|
Academic Article
|
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.
|
|
Academic Article
|
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
|
|
Academic Article
|
A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration.
|
|
Academic Article
|
SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL.
|
|
Academic Article
|
Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases.
|
|
Academic Article
|
Role of receptor tyrosine kinases in lung cancer.
|
|
Academic Article
|
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer.
|
|
Academic Article
|
Targeted molecules in small cell lung cancer.
|
|
Academic Article
|
Therapeutic targeting of the receptor tyrosine kinase Met.
|
|
Academic Article
|
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
|
|
Academic Article
|
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
|
|
Academic Article
|
Biology and novel therapeutics for neuroendocrine tumors of the lung.
|
|
Academic Article
|
Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1.
|
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
|
Academic Article
|
Receptor tyrosine kinases and inhibitors in lung cancer.
|
|
Academic Article
|
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
|
|
Academic Article
|
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.
|
|
Academic Article
|
MET receptor tyrosine kinase.
|
|
Academic Article
|
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
|
|
Academic Article
|
Non-receptor tyrosine kinase inhibitors in lung cancer.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
Differential expression of RON in small and non-small cell lung cancers.
|
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
|
Academic Article
|
Therapeutic targeting of receptor tyrosine kinases in lung cancer.
|
|
Academic Article
|
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL.
|
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
|
Academic Article
|
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
Tyrosine kinase mutations in human cancer.
|
|
Academic Article
|
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.
|
|
Academic Article
|
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.
|
|
Academic Article
|
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
|
|
Academic Article
|
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
|
|
Academic Article
|
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
|
|
Academic Article
|
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
|
|
Academic Article
|
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
|
|
Academic Article
|
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
|
Academic Article
|
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
|
|
Academic Article
|
Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer.
|
|
Academic Article
|
Key signaling pathways and targets in lung cancer therapy.
|
|
Academic Article
|
Novel targets for therapeutic agents in small cell lung cancer.
|
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
|
Academic Article
|
Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL.
|
|
Academic Article
|
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.
|
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
|
Academic Article
|
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
|
|
Academic Article
|
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
|
|
Academic Article
|
Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.
|
|
Academic Article
|
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
|
|
Academic Article
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
|
Academic Article
|
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
|
|
Academic Article
|
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.
|
|
Academic Article
|
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
|
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
|
Academic Article
|
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
|
|
Academic Article
|
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
|
|
Academic Article
|
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
|
|
Academic Article
|
Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin.
|
|
Academic Article
|
ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy.
|
|
Academic Article
|
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
|
|
Academic Article
|
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
|
|
Academic Article
|
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
|
|
Academic Article
|
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
|
|
Academic Article
|
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
|
|
Academic Article
|
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
|
|
Academic Article
|
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
|
|
Academic Article
|
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
|
|
Academic Article
|
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
|
|
Academic Article
|
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
|
|
Academic Article
|
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
|
|
Concept
|
c-Mer Tyrosine Kinase
|
|
Grant
|
Role of Paxillin in Lung Cancer
|
|
Grant
|
Role of c-Met in SCLC and Potential for Novel Therapy
|
|
Grant
|
Novel Targeted Therapy in Pancreatic Cancer
|
|
Grant
|
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
|
|
Academic Article
|
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
|